Potential therapeutic interventions to avoid or treat chronic allograft dysfunction

Transplantation

Volumn 71, Issue 11 SUPPL., 2001, Pages

  Kahan, B D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN;

ARTERY INTIMA PROLIFERATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; ENDOTHELIUM CELL; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY ALLOGRAFT REJECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ADRENAL CORTEX HORMONES; CALCINEURIN; CHRONIC DISEASE; CYCLOSPORINE; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; SIROLIMUS;

EID: 0037759067     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Cyclosporine: A base for therapy present and future
2. The role of rapamycin in chronic rejection prophylaxis: A theoretical consideration
3. The UNOS scientific renal transplant registryten years of kidney transplants
4. Fifth report of the Human Kidney Transplant Registry
5. Improved graft survival after renal transplantation in the United States, 1988 to 1996
6. Histopathology of calcineurin inhibitor-induced nephrotoxicity
7. Immunobiology and pathology of chronic rejection
8. The clinical impact of nephrotoxicity in renal transplantation
9. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
10. Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney allograft rejection
11. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice
12. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model
13. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection
14. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
15. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
16. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4
17. P-glycoprotein and drug therapy in organ transplantation
18. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats
19. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions
20. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
21. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
22. Calcineurin inhibitors cause renal afferent activation in rats: A novel mechanism of cyclosporine-induced hypertension
23. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
24. Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat (brief communication)
25. Sirolimus: Clinical results and future opportunities
26. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
27. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
28. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
29. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts a phase II trial
30. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
31. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
32. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
33. Is nonnephrotoxic immunosuppression a possibility?
34. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
35. Therapeutic monoclonal antibodies
36. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 -receptor monoclonal antibody
37. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
38. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
39. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at high risk for delayed graft function
40. Incidence and long-term cost of steroid-related side effects after renal transplantation
41. Posttransplant hyperlipidemia: The treatment dilemma
42. Risk for posttransplant diabetes mellitus with current immunosuppressive medications
43. Post-transplant diabetes mellitus. The role of immunosuppression
44. Sirolimus permits steroid withdrawal from a cyclosporine regimen
45. Reexposure to OKT3 in renal allograft recipients
46. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection
47. Muromonab-CD3 and antithymocyte globulin in renal transplantation
48. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
49. Lymphadenopathy in renal transplant patients treated with immunosuppressive antibodies (OKT3 and anti-thymocyte globulin). A report of nine cases
50. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: A report of the Tacrolimus Kidney Transplantation Rescue Study Group
51. Rapamycin: Personal algorithms for use based on 250 treated renal allograft recipients
52. Case reportsirolimus rescue therapy for refractory renal allograft rejection
53. Sirolimus rescue therapy for refractory rejection in renal transplantation
54. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells
55. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo
56. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury
57. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels
58. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
59. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
60. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model
61. Acute rejection is a major risk factor for chronic rejection
62. 1/2)